Fig 1.
Disposition of MDR/XDRAB pneumonia patients included in the analysis of the impact of tigecycline-based versus colistin-based therapy.
MDR/XDRAB, multidrug-resistant and extensively drug-resistant Acinetobacter baumannii; TGC, tigecycline; CST, colistin; SUL, sulbactam; MIN, minocycline; RFP, rifampicin; DOX, doxycycline; a for patients with multiple episodes of MDR/XDRAB pneumonia, the first episode was included in the analysis.
Table 1.
Baseline clinical characteristics of the study patients.a
Table 2.
Clinical outcomes of the study patients.a
Table 3.
Clinical outcomes of monotherapy versus combination therapy.a
Table 4.
Univariate and multivariate analysis of factors for clinical failure and 30-day mortality.